Medical Marijuana-Focused Mira Pharmaceuticals Stock Surges After Neuropsychiatric Disorders Update - Here's Why
Medical Marijuana-Focused Mira Pharmaceuticals Stock Surges After Neuropsychiatric Disorders Update - Here's Why
Friday, Mira Pharmaceuticals Inc (NASDAQ:MIRA) disclosed a discovery regarding its pre-clinical drug candidate, MIRA1a.
星期五，米拉制藥公司（納斯達克股票代碼：MIRA） 披露 關於其臨床前候選藥物Mira1a的發現。
The company's current Report on Form 8-K unveils that what was previously believed to be MIRA1a is, in fact, a newly identified molecule with distinct attributes – named MIRA-55.
該公司當前的8-K表格報告顯示，以前被認爲是Mira1a的物質實際上是一種新發現的具有不同屬性的分子——名爲 MIRA-55。
The company's patented, pre-clinical drug candidate molecule MIRA1a is an oral pharmaceutical marijuana drug candidate under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
該公司獲得專利的臨床前候選藥物分子Mira1a是一種口服藥物大麻候選藥物，正在研究中，用於治療患有焦慮和認知能力下降的成年患者，通常與早期癡呆有關。
Previous public filings highlighted positive outcomes from the MIRA1a Studies, conducted with the support of third-party organizations like Curia Global and, subsequently, Recipharm Israel Ltd.
先前的公開文件強調了Mira1a研究的積極成果，該研究是在Curia Global和隨後的Recipharm Israel Ltd等第三方組織的支持下進行的。
However, suspicions arose in late 2023 when the company, in collaboration with its contract manufacturers, began questioning the compound used in the studies.
但是，2023年底，該公司與合同製造商合作，開始質疑研究中使用的化合物，這引起了人們的懷疑。
This led to the identification of MIRA-55, a novel molecule synthesized during the manufacturing and scale-up process. The company says the results reported in earlier disclosures were attributed to the MIRA-55 compound rather than the intended MIRA1a.
這導致了 MIRA-55 的鑑定，這是一種在製造和放大過程中合成的新分子。該公司表示，先前披露中公佈的結果歸因於 MIRA-55 化合物，而不是預期的 mira1a。
Mira Pharmaceuticals views the discovery of MIRA-55 as an improvement over its predecessor.
Mira Pharmaceuticals 將 MIRA-55 的發現視爲對其前身的改進。
The newly found molecule demonstrates enhanced potency and potential efficacy, prompting the company to file a provisional patent application in early March 2024 for global protection.
這種新發現的分子顯示出增強的效力和潛在功效，促使該公司於2024年3月初提交了臨時專利申請，以獲得全球保護。
If granted, the company will secure patent rights for both MIRA1a and MIRA-55.
如果獲得批准，該公司將獲得 Mira1a 和 MIRA-55 的專利權。
Further testing is needed to validate the company's initial hypotheses. Despite ongoing investigations, the company has chosen to progress MIRA-55 as the primary compound for its oral pharmaceutical marijuana drug candidate while also maintaining its ownership of MIRA1a.
需要進一步的測試來驗證公司的初步假設。儘管調查仍在進行中，但該公司還是選擇將 MIRA-55 作爲其口服藥物大麻候選藥物的主要化合物，同時保留其對Mira1a的所有權。
Price Action: MIRA shares are up 39.01% at $1.32 on the last check Friday.
價格走勢：在週五的最後一次支票中，MIRA股價上漲39.01％，至1.32美元。
Photo via Shutterstock
照片來自 Shutterstock